Avalo director granted 20,100 stock options

Avalo Therapeutics, Inc. director Gilla Kaplan received a grant of stock options linked to the company’s common stock.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. director Gilla Kaplan received a grant of stock options linked to the company’s common stock. The award covers 20,100 options with an exercise price of $13.96 per share and expires on June 2, 2036.

According to the terms, the option vests 100% on the first anniversary of the grant date, as long as the director continues to serve through that date. After this grant, Kaplan holds 20,100 stock options directly, giving equity-based, long-term incentive aligned with future company performance.

Insider Trade Summary

Grant/Award: 20,100 shares

Grant/Award 1 txn

Insider KAPLAN GILLA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,100 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

Key Figures

Option grant size: 20,100 options Exercise price: $13.96 per share Post-grant option holdings: 20,100 options +2 more

5 metrics

Option grant size 20,100 options Stock Option (Right to Buy) granted to director

Exercise price $13.96 per share Conversion or exercise price of stock option

Post-grant option holdings 20,100 options Total derivative securities following transaction

Expiration date June 2, 2036 Option expiration date

Vesting schedule 100% after 1 year Vests on first anniversary of grant if service continues

Key Terms

Stock Option (Right to Buy), exercise price, vests 100% on the first anniversary, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 13.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests 100% on the first anniversary financial

"The stock option vests 100% on the first anniversary of the date of grant"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalo Therapeutics (AVTX) director Gilla Kaplan report on this Form 4?

Gilla Kaplan reported receiving a grant of stock options for 20,100 shares of Avalo Therapeutics common stock. These options are a form of equity compensation and give the director the right to buy shares at a fixed exercise price in the future.

How many Avalo Therapeutics (AVTX) stock options were granted and at what price?

The Form 4 shows a grant of 20,100 stock options with an exercise price of $13.96 per share. This price is the amount the director must pay per share if the options are exercised after vesting, regardless of future market prices.

When do Gilla Kaplan’s Avalo Therapeutics (AVTX) stock options vest and expire?

The stock options vest 100% on the first anniversary of the grant date, provided the director continues serving through that vesting date. They carry an expiration date of June 2, 2036, after which any unexercised options will no longer be usable.

Is this Avalo Therapeutics (AVTX) Form 4 a stock purchase or a compensation grant?

This Form 4 reflects a compensation-related grant, not an open-market stock purchase. The transaction code “A” and description indicate it is a grant or award of options, giving the director rights to acquire shares later rather than buying shares in the market now.

How many Avalo Therapeutics (AVTX) options does Gilla Kaplan hold after this transaction?

After this grant, the director is reported as holding 20,100 stock options directly. These options are tied to Avalo Therapeutics common stock and represent potential future share ownership if they vest and are exercised before the June 2, 2036 expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAPLAN GILLA

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.96	06/02/2026		A		20,100		(1)	06/02/2036	Common Stock	20,100	$0	20,100	D

Explanation of Responses:

1. The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)